Xilio Therapeutics
35 hedge funds and large institutions have $16.2M invested in Xilio Therapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 5 closing their positions.
0.17% more ownership
Funds ownership: 3.11% → 3.28% (+0.17%)
0% more funds holding
Funds holding: 35 → 35 (0)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
1% less capital invested
Capital invested by funds: $16.3M → $16.2M (-$139K)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$1.01M |
| 2 |
Morgan Stanley
New York
|
+$218K |
| 3 |
Squarepoint
New York
|
+$178K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$58K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$26.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$281K |
| 2 |
BlackRock
New York
|
-$54.8K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$41.9K |
| 4 |
Millennium Management
New York
|
-$37K |
| 5 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$30.8K |
XLO Hedge Fund Activity: Q2 2025 in Review
35 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2025, worth a combined $16.2M — down 0.85% from $16.3M a quarter earlier.
Fund positioning in XLO was balanced in Q2 2025: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 11 trimmed.
The largest buyer was Ghisallo Capital Management, opening a new position worth an estimated $1.01M. The largest seller was Fidelity Investments, cutting an estimated $281K.
- 35 institutional investors held Xilio Therapeutics (XLO) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $16.2M of Xilio Therapeutics stock for Q2 2025, down 0.85% quarter-over-quarter.
- 5 funds opened new Xilio Therapeutics positions in Q2 2025 and 5 closed out, a net change of 0 holders.
- The largest Xilio Therapeutics buyer in Q2 2025 was Ghisallo Capital Management, an estimated $1.01M added.
- The largest Xilio Therapeutics seller in Q2 2025 was Fidelity Investments, an estimated $281K sold.
Based on aggregated 13F filings for Q2 2025.